CrossrefInfokarte
Efficacy, Safety, and Exploratory Prognostic Factors of TACE-HAIC Plus Lenvatinib with Tislelizumab or Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study
Journal of Hepatocellular Carcinoma · 2026-11 · Volume 13 · 1-16
DOI: 10.2147/jhc.s650816 ↗Abstract
Kein Abstract verfügbar.
EUVIMED